RSS-Feed abonnieren
DOI: 10.1055/s-2001-18863
Disseminated Intravascular Coagulation in Sepsis
Publikationsverlauf
Publikationsdatum:
06. Dezember 2001 (online)
![](https://www.thieme-connect.de/media/sth/200106/lookinside/thumbnails/10.1055-s-2001-18863-1.jpg)
ABSTRACT
Disseminated intravascular coagulation (DIC) has been considered a rather rare syndrome characterized by severe bleeding. In fact, both of these beliefs are wrong. Bleeding is fairly rare in DIC. The clotting parameters are usually normal unless the DIC is fulminating. It is usually thought that fibrinogen may be low or absent in DIC. However, afibrinogenemia is rare. Fibrinogen is usually high in DIC because of the high rate of fibrinogen manufacture by the liver in response to stress. DIC is very common and most cases are never diagnosed. This is because it has been hard to find fibrin thrombi in autopsy cases and because acute severe bleeding is uncommon. The reason fibrin thrombi are rare may be because they have been lysed by endogenous fibrinolytic enzymes before the autopsy. The appearance of endogenous fibrinolytic response could be a defense mechanism to lyse the microclots of DIC. In fact, this response is often successful. This defense can be aided by the administration of plasminogen activators that will lyse the clots. Heparin has been used for the treatment of DIC but has proved useless and is, in fact, dangerous. This is because heparin will not dissolve clots and may actually promote platelet agglutination. Administration of plasminogen activators will actually prevent bleeding diathesis.
KEYWORD
Sepsis - septic shock - disseminated intravascular coagulation - DIC - plasminogen activator
REFERENCES
- 1 Landois. Tranfusion des Blutes. Leipzig 1875
- 2 Schneider C L. Fibrin embolism with defibrination as one of the end results during placenta abruptio. Surg Gynecol Obstet . 1951; 92 27-34
- 3 Hardaway R M, McKay D G, Williams J H. Lower nephron nephrosis. Am J Surg . 1954; 87 41-49
- 4 Hardaway R M. Disseminated intravascular coagulation syndromes. Arch Surg . 1961; 83 842-850
- 5 Hardaway R M. Syndrome of Disseminated Intravascular Coagulation with Special Reference to Shock and Hemorrhage. Springfield, IL: Charles C Thomas; 1966
- 6 Hardaway R M, James J M, Anderson R W. Intensive study and treatment of shock in man. JAMA . 1967; 199 779-790
- 7 Hardaway R M. A review of septic shock. Am Surg . 2000; 66 22-29
- 8 Singer S N, Nicolson G L. The fluid model of the structure of cell membranes. Science . 1972; 720 175-180
- 9 Schwartz R S, Chiu D TY, Lubin B. Studies on the organization of plasma membrane phospholipids in human erythrocyte. In: Kracheber WE, Eaton JW, Aston J, et al, eds. Erythrocyte Membranes, 3 Recent Chemical and Experimental Advances New York: Arliss 1984: 89-122
- 10 Chiu D, Lubin B, Shobet S B. Erythrocyte membrane lipid organization during the sickling process. Br J Hematol . 1979; 41 223-234
- 11 Feola M, Simons J, Conigardo P C. Toxicity of polymerized hemoglobin solution. Surg Gynecol Obstet . 1988; 66 211-222
- 12 Tuomanen E. Breaching the blood-brain barrier. Sci Am . 1993; 80-84
- 13 Hardaway R M, McKay D G. Disseminated intravascular coagulation: a cause of shock. Ann Surg . 1959; 149 462-470
- 14 Hardaway R M, Johnson O. Clotting mechanism in endotoxin shock-a manifestation of DIC. Ann Surg . 1961; 154 791-802
- 15 Hardaway R M, Williams C H, Yang S un. A new approach to the treatment of experimental septic shock. J Surg Res . 1996; 61 311-316
- 16 Hardaway R M, Harke H, Williams C H. Fibrinolytic agents: a new approach to the treatment of ARDS. Adv Ther . 1994; 11 43-51
- 17 Hardaway R M. Traumatic and septic shock alias post-trauma critical illness. Br J Surg . 1998; 85 1473-1479
- 18 Hardaway R M. Disseminated intravascular coagulation and the treatment of ARDS with plasminogen activator. Hematol Rev . 1994; 9 3-19
- 19 Hardaway R M. Treatment of ARDS. Drugs Today . 1994; 30 645-653
- 20 Aiuto L T, Barone S R, Cohen P S. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med . 1997; 25 1079-1082
- 21 Horne M K. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med . 1997; 25 909 Editorial
- 22 Zenz W, Bodo Z, Zobel G. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med . 1998; 25 969-971
- 23 Hardaway R M. Shock and disseminated intravascular coagulation. In: Hardaway RM, ed. Shock: The Reversible Stage of Dying Littleton, MA: Year Book 1988: 321-329
- 24 Hardaway R M, Johnson D G, Houchin D N. Influence of stress on fibrinogen. J Trauma . 1964; 4 673-676
- 25 Hardaway R M. Mechanism of action of fibrinolysin in the prevention of irreversible hemorrhagic shock. Ann Surg . 1963; 157 305-309
- 26 Adams W H. Bleeding. In: Problems in Critical Care, Vol 3. Philadelphia: Lippincott 1989: 108-138
- 27 Hardaway R M, Drake D C. Prevention of ``irreversible'' hemorrhagic shock with fibrinogen. Ann Surg . 1963; 157 39-47
- 28 Hardaway R M, Johnson D G. Influence of fibrinolysin on shock. JAMA . 1963; 183 597-599
- 29 Hardaway R M, Williams C H, Marvasti M. Prevention of ARDS with plasminogen activator. Crit Care Med . 1990; 18 1413-1418
- 30 Hardaway R M. Trauma sepsis and DIC. J Intensive Care Med . 1995; 10 145-152